AC Immune Reports Positive Trial Data for Parkinson's Disease Drug
AC Immune (NASDAQ: ACIU) reported positive safety and tolerability results from Part 1 of its Phase 2 VacSYn trial for the experimental therapy ACI-7104, designed to treat Parkinson’s disease. The company noted that these findings support further development of the drug candidate. The announcement led to a rise in premarket trading as investors reacted positively to the early-stage data. While no efficacy results were disclosed at this stage, the safety profile is seen as an important milestone for advancing clinical research into potential treatments for Parkinson’s disease.
Tickers: $ACIU